Cryoport, Inc. has launched a Temperature Controlled Logistics Consulting Division to help life sciences companies develop strategies for global cold chain logistics management for biologics. The new division will be led by Tamie Joeckel, senior vice president of Client Services. Ms. Joeckel has more than 25 years of pharmaceutical industry logistics experience having worked with AmerisourceBergen, McKesson, PAREXEL and Dohmen Life Sciences, and having participated in the launch strategies for more than 20 biopharmaceutical therapies.  
 
The launch aims to address the increase in cellular based therapies, including immunotherapies, stem cells and CAR T-cells, which creates challenges for the life sciences industry, including how to obtain, properly store and transport the growing number of new temperature sensitive therapies.
 
Each facility that looks to successfully implement cellular based programs must develop cryogenic storage, distribution and fulfillment solutions that are capable of tracking individual patient- based drug product, maintaining the proper environment, and providing proof from collected and vital monitoring information regarding the “chain of condition” and “chain of custody.” Many of these therapies require both cold chain and frozen chain segments within the programs and maintaining cell viability is the greatest risk. 
 
Jerrell Shelton, chief executive officer of Cryoport, said, “We are indeed excited about our expansion into consulting. Our many years of systems and logistics solutions development have put Cryoport in a unique position to provide life sciences industry companies with a wealth of knowledge and best practices for cryogenic cold chain logistics.